Jan 22, 2025 · With antibiotic resistance on the rise, researchers at the University of Virginia School of Medicine have developed innovative computer models that could give antibiotics the precision to target only specific bacteria in specific parts of the body. This approach seeks to address the rising challenge of antibiotic resistance, which jeopardises one of modern medicine’s most essential weapons ...

Jan 16, 2025 · The University of Virginia Center for Diabetes Technology and Tandem Diabetes Care have entered into a multi-year collaboration agreement to advance research and development in fully automated insulin delivery systems. This partnership will leverage the UVA Center’s groundbreaking work in improving diabetes care through technology-based interventions, along with Tandem’s expertise in ...

Sep 25, 2024 · Cookie Type Duration Description; cookielawinfo-checkbox-advertising-targeting: persistent: 1 year: The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".

Jan 16, 2025 · Streamlining macrocyclic therapeutic development. Platforms such as PeptiDream’s drug discovery platform system 17 have facilitated easier synthesis and screening of macrocyclic peptide libraries for lead compounds (eg, the PD-L1 macrocycle from Figure 1). Another approach to macrocyclic library design is to generate pools of peptidic scaffolds that are designed to possess qualities such as ...

Jan 21, 2025 · Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics, has announced the launch of Nuvia wPrime 2A Media.This scalable mixed-mode chromatography resin combines weak anion exchange and hydrophobic interaction (AEX-HIC) techniques, making it ideal for biomolecule purification at both small and large scales.

Jan 23, 2024 · Dr Espen Basmo Ellingsen. University of Oslo . Dr Ellingsen is a Medical Doctor and holds a PhD in cancer immunology from the University of Oslo. Background in translational research from the Institute for Cancer Research at Oslo University Hospital, focusing on therapeutic cancer vaccination, induced immune responses, and their impact on the tumor microenvironment.

Jan 6, 2025 · Researchers at the Huntsman Cancer Institute, University of Utah, have identified a gene variant found in high-altitude Andean populations that could serve as a novel biomarker for predicting the severity of diseases and responses to treatments for certain blood cancers.This breakthrough could pave the way for personalised treatment strategies in blood cancer patients.

Dec 12, 2024 · Novartis has partnered with PTC Therapeutics to develop and commercialise PTC518, a promising small molecule therapy targeting the root cause of Huntington’s disease.. In a move that could significantly impact the treatment landscape for Huntington’s disease, Novartis has secured an exclusive licensing agreement with …

Sep 19, 2024 · Based on the positive efficacy and safety data generated in Phase I and II, the plan is to initiate a Phase III programme for mesdopetam. Following successful interactions at the End-of-Phase 2 meeting for mesdopetam with the US Food and Drug Administration (FDA) earlier this year we now look forward to the interactions with European drug regulatory authorities in the autumn for the start of a ...

Dec 4, 2024 · Insilico Medicine’s AI-designed drug ISM5939 has received FDA IND clearance for treating solid tumours. By targeting ENPP1, it enhances anti-tumour immunity and is set to begin Phase I trials soon.